Polatuzumab vedotin-piiq | CD markers inhibitor | Read Reviews & Product Use Citations

Polatuzumab vedotin-piiq (polatuzumab vedotin, DCDS4501A, RG7596) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody against CD79b (a B cell receptor component) and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). It is used for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

CAS No. 1313206-42-6

Click to purchase products related to Polatuzumab vedotin-piiq

Purity & Quality Control

≥99

Choose Selective CD markers Inhibitors

Biological Activity

Description	Polatuzumab vedotin-piiq (polatuzumab vedotin, DCDS4501A, RG7596) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody against CD79b (a B cell receptor component) and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). It is used for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

References
[1] Deeks ED. Drugs. 2019;79(13):1467-1475.

References

[1] Deeks ED. Drugs. 2019;79(13):1467-1475.

Product Details

CAS No.	1313206-42-6
ADC antiody	Polatuzumab
ADC cytotoxin	MMAE
Formulation	1xPBS
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field